Ofatumumab is an anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology.[rx] Ofatumumab works by recognizing antigens that are expressed on the tumor cells in certain cancers; however, the antigen is not tumor-specific and can also be found in normal B-cells.[rx] Ofatumumab was first approved by the FDA in 2009.[rx] It is used in treating recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient’s profile and previous treatment history.[rx] Although it has a similar molecular mechanism of action as rituximab, another CD-20 monoclonal antibody used in the treatment of rheumatoid arthritis and B-cell non-Hodgkin’s lymphoma, ofatumumab has a higher affinity towards CD20.[rx]
Ofatumumab is available for intravenous administration and is marketed as Arzerra. In Phase III clinical trials consisting of subjects with relapsing forms of multiple sclerosis (RMS), subcutaneous administration of ofatumumab reduced the number of relapses and delayed disease progression. In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of RMS in adults.[rx] The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020.[rx] The potential therapeutic use of ofatumumab in various lymphomas and rheumatoid arthritis has also been investigated.[rx]
Mechanism of action
CD20 is expressed on normal pre-B lymphocytes and mature B lymphocytes, as well as malignant B lymphocytes. Numerous studies demonstrate that the depletion of B-cells can significantly alleviate symptoms of many forms of leukemia and lymphoma, which are malignancies associated with B-cell dysfunctions and high expression of CD20.[rx]
Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small and large extracellular loops of the CD20 molecule. The Fab domain of ofatumumab binds to CD20, and this drug-target interaction does not result in immediate shedding and internalization of CD20 from the plasma membrane of B lymphocytes.[rx,rx] This allows ofatumumab to persist on the B lymphocyte cell surface for an extended period and recruit immunological molecules or FcR-expressing innate effectors, such as macrophages, that mediate immune effector functions with strong cytotoxic effects. These immune effector functions include complement-dependent cytotoxicity (CCD) and antibody-dependent cellular cytotoxicity (ADCC), which promote the lysis of malignant B-cells. Complement-dependent cytotoxicity (CDC) involves the translocation of the CD20 molecule into lipid rafts, which are involved in cell signaling and receptor trafficking.[rx]
The mechanism by which ofatumumab exerts a therapeutic effect in multiple sclerosis patients is unknown but is presumed to still occur as a consequence of its ability to bind CD20.[rx]
Indications
- Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.[rx]
- In patients with recurrent or progressive CLL, ofatumumab is indicated for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.[rx]
- Ofatumumab is indicated for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.[rx]
- Ofatumumab is also indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, including active secondary progressive disease, clinically isolated syndrome, and relapsing-remitting disease.[rx]
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Lymphocytic Leukemia (CLL) – Refractory
- Clinically Isolated Syndrome (CIS)
- Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Active Secondary Progressive Multiple Sclerosis (SPMS)
- Progressive Chronic Lymphocytic Leukaemia (CLL)
- Recurrent Chronic Lymphocytic Leukaemia (CLL)
Use in Cancer
Ofatumumab is approved to be used alone or with other drugs to treat:
- Chronic lymphocytic leukemia (CLL).
- It is used alone as extended treatment in patients with recurrent or progressive disease who are in complete or partial response after at least two other types of treatment.
- It is used with fludarabine phosphate and cyclophosphamide in patients with relapsed disease.
- It is used alone in patients who have not gotten better with other drugs.
- It is used with chlorambucil in patients who have never been treated and cannot receive specific chemotherapy.
Ofatumumab is also being studied in the treatment of other types of cancer.
Contraindications
The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:
- a bad infection
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- angina, a type of chest pain
- pregnancy
- chronic obstructive pulmonary disease
- resolved hepatitis B
- reactivation of hepatitis B infection
- progressive multifocal leukoencephalopathy, a type of brain infection
- are allergic to ofatumumab or any ingredients of the medication
- have active hepatitis B infection
- have any severe infection
- have or have had progressive multifocal leukoencephalopathy (PML)
- have a severely reduced immune system
- have active cancer
Dosage
Strengths: 20 mg/mL; 20 mg/0.4 mL
Chronic Lymphocytic Leukemia
ARZERRA:
PREVIOUSLY UNTREATED CLL:
- 300 mg IV on Day 1 followed by 1000 mg IV on Day 8 (Cycle 1) followed by 1000 mg IV on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until the best response or a maximum of 12 cycles
RELAPSED CLL:
In combination with fludarabine and cyclophosphamide:
- 300 mg IV on Day 1 followed by 1000 mg IV on Day 8 (Cycle 1), followed by
- 1000 mg IV on Day 1 of subsequent 28-day cycles for a maximum of 6 cycles
EXTENDED TREATMENT IN CLL:
As a single agent:
- 300 mg IV on Day 1 followed by 1000 mg IV on Day 8 followed by 1000 mg IV 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years
REFRACTORY CLL:
- 300 mg IV on Day 1 followed by 2000 mg IV weekly for 7 doses (infusions 2 through 8), followed 4 weeks later by 2000 mg IV every 4 weeks for 4 doses (infusions 9 through 12)
PREMEDICATION:
Patients should receive premedication 30 minutes to 2 hours before each infusion:
Previously Untreated CLL, Relapsed CLL, or Extended Treatment in CLL:
- Infusions 1 and 2: IV corticosteroid (prednisolone or equivalent) 50 mg AND oral acetaminophen 1000 mg AND oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg [or equivalent])
- Infusions 3 and beyond (up to 13 infusions in previously untreated CLL; up to 14 infusions in extended treatment in CLL): IV corticosteroid (prednisolone or equivalent) 0 to 50 mg (the corticosteroid may be reduced or omitted for subsequent infusions if a Grade 3 or greater infusion-related adverse event did not occur with the preceding infusion) AND oral acetaminophen 1000 mg AND oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg [or equivalent])
Refractory CLL:
- Infusions 1, 2, and 9: IV corticosteroid (prednisolone or equivalent) 100 mg AND oral acetaminophen 1000 mg AND oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg [or equivalent])
- Infusions 3 to 8: IV corticosteroid (prednisolone or equivalent) 0 to 100 mg (the corticosteroid may be reduced or omitted for subsequent infusions if a Grade 3 or greater infusion-related adverse event did not occur with the preceding infusion) AND oral acetaminophen 1000 mg AND oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg [or equivalent])
- Infusions 10 to 12: IV corticosteroid (prednisolone or equivalent) 50 to 100 mg (the corticosteroid may be given at a reduced dose of 50 mg to 100 mg if a Grade 3 or greater infusion-related adverse event did not occur with Infusion 9) AND oral acetaminophen 1000 mg AND oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg [or equivalent])
ADMINISTRATION:
PREVIOUSLY UNTREATED CLL AND EXTENDED TREATMENT IN CLL:
- Initiate the first 300 mg dose IV at 3.6 mg/hr (12 mL/hr) for 30 minutes
- For subsequent infusions of 1000 mg, initiate at 25 mg/hr (25 mL/hr); initiate infusion at 12 mg/hour if a Grade 3 or greater infusion-related reaction was experienced during the previous infusion
- In the absence of an infusion-related reaction, the rate of infusion may be increased every 30 minutes:
Infusion rates for this drug in previously untreated CLL relapsed CLL, and extended treatment in CLL:
- 300 mg IV at 12 mL/hr for the first 30 minutes; if tolerated, increase to 25 mL/hr for 30 minutes; if tolerated increase to 50 mL/hr for 30 minutes; if tolerated increase to 100 mL/hr for 30 minutes; if tolerated increase to 200 mL/hr for 30 minutes; if tolerated increase to 300 mL/hr for 30 minutes; if tolerated increase to 400 mL/hr for the remainder of the infusion. The median duration of infusion is 4.2 to 4.4 hours.
REFRACTORY CLL:
- Infusion 1 (300 mg dose): Initiate infusion at 3.6 mg/hr (12 mL/hour)
- Infusion 2 (2000 mg dose): Initiate infusion at 24 mg/hr (12 mL/hour)
- Infusions 3 through 12 (2000 mg doses): Initiate infusion at 50 mg/hr (25 mL/hour)
In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes:
- 300 mg IV at 12 mL/hr for the first 30 minutes; if tolerated, increase to 25 mL/hr for 30 minutes; if tolerated increase to 50 mL/hr for 30 minutes; if tolerated increase to 100 mL/hr for 30 minutes; if tolerated increase to 200 mL/hr for 30 minutes; if tolerated increase to 300 mL/hr for 30 minutes; if tolerated increase to 400 mL/hr for the remainder of the infusion. The median duration of infusion is 4.2 to 4.4 hours.
Multiple Sclerosis
KESIMPTA:
- 20 mg subcutaneously at Weeks 0, 1, and 2, followed by 20 mg subcutaneously once a month starting at Week 4
NOTE: If a dose is missed, administer it as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.
Dose Adjustments
INFUSION RATE DOSE MODIFICATION FOR INFUSION REACTIONS:
- Interrupt infusion for infusion reactions of any severity.
- Therapy may be resumed at the discretion of the physician.
- The following infusion rate modifications can be used as a guide: if the infusion reaction resolves or remains less than or equal to Grade 2, resume infusion with the following modifications according to the initial Grade of the infusion reaction:
- Grade 1 or 2: Infuse at one-half of the previous infusion rate.
- Grade 3 or 4: Infuse at a rate of 12 mL/hour.
- After resuming the infusion, the infusion rate may be increased according to the standard schedule, based on patient tolerance.
- Consider permanent discontinuation of therapy if the severity of the infusion reaction does not resolve to less than or equal to Grade 2 despite adequate clinical intervention.
- Permanently discontinue therapy for patients who develop an anaphylactic reaction.
Side Effects
The Most Common
- signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat)
- muscle spasms
- stuffy or runny nose
- diarrhea
- headache
- difficulty sleeping
- difficulty breathing or swallowing
- heavy sweating
- swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
- hoarseness
- sudden reddening of the face, neck, or upper chest
- weakness
- unusual bleeding or bruising
- pale skin
- pinpoint, flat, round, red spots under the skin
- rash
- hives
- fever, chills, cough, sore throat, or other signs of infection
- pain in arms, back, neck, or jaw
- chest pain,
- fast heartbeat
- fainting
More Common
- low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath; or
- signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.
- chills
- headache
- increased frequency of cold symptoms or sinus infections (e.g., sore throat, runny nose, nasal congestion, or facial pain)
- muscle pain
- redness, pain, itching, or swelling at the injection site
- tiredness
- fever
- signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
Rare
- pain, redness, swelling, or itching where the medicine was injected;
- right-sided upper stomach pain, vomiting, loss of appetite, yellowing of your skin or eyes, and not feeling well;
- a lung infection–fever, chills, cough with mucus, chest pain, feeling short of breath;
- side effects during an infusion;
- irritation where an injection was given;
- fever, low blood cell counts;
- cold symptoms such as stuffy nose, sneezing, and sore throat;
- cough, chest tightness, trouble breathing, lung infection;
- diarrhea, nausea;
- rash; or
- headache, tiredness.
Drug Interaction
| Abatacept | The risk or severity of adverse effects can be increased when Abatacept is combined with Ofatumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Ofatumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Ofatumumab. |
| Adenovirus type 7 vaccine live | The risk or severity of infection can be increased when the Adenovirus type 7 vaccine live is combined with Ofatumumab. |
| Aducanumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Aducanumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ofatumumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Ofatumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ofatumumab. |
| Alirocumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Alirocumab. |
| The allogeneic processed thymus tissue | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ofatumumab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Ofatumumab. |
| Amivantamab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Amivantamab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Ofatumumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Ofatumumab. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Anifrolumab. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ansuvimab. |
| Anthrax immune globulin human | The therapeutic efficacy of Anthrax immune globulin humans can be decreased when used in combination with Ofatumumab. |
| Anthrax vaccine | The risk or severity of infection can be increased when the Anthrax vaccine is combined with Ofatumumab. |
| antilymphocyte immunoglobulin (horse) | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Antilymphocyte immunoglobulin (horse). |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ofatumumab. |
| Apremilast | The risk or severity of adverse effects can be increased when Apremilast is combined with Ofatumumab. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ofatumumab. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Articaine. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Asfotase alfa. |
| AstraZeneca COVID-19 Vaccine | The therapeutic efficacy of the AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ofatumumab. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Atezolizumab. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Atoltivimab. |
| Avelumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Avelumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Ofatumumab. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Ofatumumab. |
| Bacillus Calmette-Guerin substrain Connaught live antigen | The risk or severity of infection can be increased when Bacillus Calmette-Guerin substrain Connaught live antigen is combined with Ofatumumab. |
| Bacillus Calmette-Guerin substrain Russian BCG-I live antigen | The therapeutic efficacy of Bacillus Calmette-Guerin substrain Russian BCG-I live antigen can be decreased when used in combination with Ofatumumab. |
| Bacillus Calmette-Guerin substrain tice live antigen | The risk or severity of infection can be increased when Bacillus Calmette-Guerin substrain tice live antigen is combined with Ofatumumab. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bamlanivimab. |
| Baricitinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Ofatumumab. |
| BCG vaccine | The risk or severity of infection can be increased when the BCG vaccine is combined with Ofatumumab. |
| Bebtelovimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bebtelovimab. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ofatumumab. |
| Belantamab mandolin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mandolin. |
| Belatacept | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Ofatumumab. |
| Belumosudil | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belumosudil. |
| Bendamustine | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bendamustine. |
| Benralizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Benralizumab. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Benzyl alcohol. |
| Besilesomab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Besilesomab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Ofatumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Ofatumumab. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bezlotoxumab. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bimekizumab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Ofatumumab. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Blinatumomab. |
| Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ofatumumab. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Ofatumumab. |
| Bosutinib | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ofatumumab. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Brentuximab vedotin. |
| Brodalumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Brodalumab. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Brolucizumab. |
| Budesonide | The risk or severity of adverse effects can be increased when Budesonide is combined with Ofatumumab. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Bupivacaine. |
| Burosumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Burosumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Ofatumumab. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Butamben. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Cabazitaxel. |
| Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Ofatumumab. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Ofatumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ofatumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ofatumumab. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Capsaicin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ofatumumab. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Ofatumumab. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Ofatumumab. |
| Casirivimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Casirivimab. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Catumaxomab is combined with Ofatumumab. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Cemiplimab. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Certolizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Ofatumumab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ofatumumab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ofatumumab. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Chloroprocaine. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ofatumumab. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Cilgavimab. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Cinchocaine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ofatumumab. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Ofatumumab. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ofatumumab. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ofatumumab. |
| Clostridium tetani toxoid antigen (formaldehyde inactivated) | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Cocaine. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Ofatumumab. |
| Corticotropin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Ofatumumab. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ofatumumab. |
| Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ofatumumab. |
| Cyclosporine | Ofatumumab may increase the immunosuppressive activities of Cyclosporine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Ofatumumab. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ofatumumab. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ofatumumab. |
| Daratumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Daratumumab. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ofatumumab. |
| Dasatinib | The risk or severity of adverse effects can be increased when Dasatinib is combined with Ofatumumab. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ofatumumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Ofatumumab. |
| Deflazacort | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Deflazacort. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Ofatumumab. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ofatumumab. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Deucravacitinib. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ofatumumab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ofatumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Ofatumumab. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Ofatumumab. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Difluocortolone. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ofatumumab. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dimethyl fumarate. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Diphenhydramine. |
| Proximal fumarate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Diroximel fumarate. |
| Docetaxel | The risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab. |
| Dostarlimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dostarlimab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Ofatumumab. |
| Dulaglutide | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dulaglutide. |
| Dupilumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dupilumab. |
| Durvalumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Durvalumab. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Dyclonine. |
| Ebola Zaire vaccine (live, attenuated) | The therapeutic efficacy of the Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ofatumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Ofatumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Ofatumumab. |
| Eflapegrastim | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eflapegrastim. |
| Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eftrenonacog alfa. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Elotuzumab is combined with Ofatumumab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Emapalumab. |
| Emicizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Emicizumab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Ofatumumab. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eptinezumab. |
| Erenumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Erenumab. |
| Eribulin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Eribulin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ofatumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Ofatumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Ofatumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Ofatumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Ofatumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Ofatumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Ofatumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Ofatumumab. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Ofatumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Ofatumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Ofatumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Ofatumumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Ofatumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Ofatumumab. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Etidocaine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Ofatumumab. |
| Everolimus | The risk or severity of adverse effects can be increased when Everolimus is combined with Ofatumumab. |
| Evolocumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Evolocumab. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fanolesomab. |
| Filgotinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Filgotinib. |
| Fingolimod | Ofatumumab may increase the immunosuppressive activities of Fingolimod. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Ofatumumab. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Ofatumumab. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Ofatumumab. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ofatumumab. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Ofatumumab. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Ofatumumab. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ofatumumab. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ofatumumab. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ofatumumab. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fluprednisolone. |
| Fluticasone | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fluticasone furoate. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ofatumumab. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Fremanezumab. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Galcanezumab. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Ofatumumab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ofatumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Ofatumumab. |
| Golimumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Golimumab. |
| Guselkumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Guselkumab. |
| Haemophilus influenza type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ofatumumab. |
| Hepatitis A Vaccine | The therapeutic efficacy of the Hepatitis A Vaccine can be decreased when used in combination with Ofatumumab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ofatumumab. |
| Hepatitis B Vaccine (Recombinant) | The therapeutic efficacy of the Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ofatumumab. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The risk or severity of infection can be increased when the Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ofatumumab. |
| Human cytomegalovirus immune globulin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Human cytomegalovirus immune globulin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ofatumumab. |
| Human Rho(D) immune globulin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Human Rho(D) immune globulin. |
| Human varicella-zoster immune globulin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Human varicella-zoster immune globulin. |
| Hydrocortisone acetate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Hydrocortisone acetate. |
| Hydrocortisone butyrate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Hydrocortisone butyrate. |
| Hydrocortisone succinate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Hydrocortisone succinate. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ofatumumab. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ofatumumab. |
| Ibalizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ibalizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ibrutinib. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Ofatumumab. |
| Idarucizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Idarucizumab. |
| Idelalisib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Ofatumumab. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Ofatumumab. |
| Imdevimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Imdevimab. |
| Imlifidase | The therapeutic efficacy of Ofatumumab can be decreased when used in combination with Imlifidase. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Ofatumumab. |
| Inebilizumab | The risk or severity of infection can be increased when Ofatumumab is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Ofatumumab. |
| ipilimumab | The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ofatumumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Ofatumumab. |
| Isatuximab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Isatuximab. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ofatumumab. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ixekizumab. |
| Janssen COVID-19 Vaccine | The therapeutic efficacy of the Janssen COVID-19 Vaccine can be decreased when used in combination with Ofatumumab. |
| Japanese encephalitis virus strain a 14-14-2 antigen (formaldehyde inactivated) | The therapeutic efficacy of Japanese encephalitis virus strain a 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Lanadelumab. |
| Leflunomide | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ofatumumab. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Levobupivacaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Lidocaine. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Ofatumumab. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Ofatumumab. |
| Loncastuximab tesirine | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Loncastuximab tesirine. |
| Lopinavir | The serum concentration of Ofatumumab can be increased when it is combined with Lopinavir. |
| Maftivimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Maftivimab. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Ofatumumab. |
| Margetuximab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Margetuximab. |
| Measles virus vaccine live attenuated | The therapeutic efficacy of the Measles virus vaccine live attenuated can be decreased when used in combination with Ofatumumab. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ofatumumab. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Ofatumumab. |
| Meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | The therapeutic efficacy of Meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ofatumumab. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ofatumumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ofatumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Ofatumumab. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Ofatumumab. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Ofatumumab. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ofatumumab. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ofatumumab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Ofatumumab. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ofatumumab. |
| Moderna COVID-19 Vaccine | The therapeutic efficacy of the Moderna COVID-19 Vaccine can be decreased when used in combination with Ofatumumab. |
| Modified vaccinia ankara | The therapeutic efficacy of Modified vaccinia Ankara can be decreased when used in combination with Ofatumumab. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Mogamulizumab. |
| Mometasone furoate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Mometasone furoate. |
| Monomethyl fumarate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Monomethyl fumarate. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Mosunetuzumab. |
| Mumps virus strain B level jeryl Lynn live antigen | The therapeutic efficacy of Mumps virus strain B level jeryl Lynn lives antigen can be decreased when used in combination with Ofatumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Ofatumumab. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ofatumumab. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ofatumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Natalizumab. |
| Necitumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Necitumumab. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Ofatumumab. |
| Nilotinib | The risk or severity of adverse effects can be increased when Nilotinib is combined with Ofatumumab. |
| Nivolumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Nivolumab. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ofatumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ofatumumab. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Ofatumumab. |
| Odesivimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Odesivimab. |
| Olaparib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Olaparib. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Ofatumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Ofatumumab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ofatumumab. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Oxybuprocaine. |
| Ozanimod | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab. |
| Palbociclib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Palbociclib. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ofatumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Ofatumumab. |
| Panobinostat | The risk or severity of adverse effects can be increased when Panobinostat is combined with Ofatumumab. |
| Pazopanib | The risk or severity of adverse effects can be increased when Pazopanib is combined with Ofatumumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ofatumumab. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ofatumumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ofatumumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ofatumumab. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Peginterferon beta-1a. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pembrolizumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ofatumumab. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Ofatumumab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Ofatumumab. |
| Pertussis vaccine | The therapeutic efficacy of the Pertussis vaccine can be decreased when used in combination with Ofatumumab. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Pertuzumab is combined with Ofatumumab. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Phenol. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ofatumumab. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ofatumumab. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ofatumumab. |
| Polatuzumab vedotin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Polatuzumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Ofatumumab. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ponesimod. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pralatrexate. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Pramocaine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Ofatumumab. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Ofatumumab. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Prilocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Procaine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ofatumumab. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Proparacaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Propoxycaine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ofatumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Ofatumumab. |
| Rabies immune globulin, human | The therapeutic efficacy of Rabies immune globulin, humans can be decreased when used in combination with Ofatumumab. |
| Rabies virus inactivated antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ofatumumab. |
| Rabies virus inactivated antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ofatumumab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ofatumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ofatumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ofatumumab. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ravulizumab. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Raxibacumab. |
| Reslizumab | The risk or severity of adverse effects can be increased when Reslizumab is combined with Ofatumumab. |
| Rilonacept | The risk or severity of adverse effects can be increased when Rilonacept is combined with Ofatumumab. |
| Risankizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Risankizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Ofatumumab. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Ofatumumab. |
| Romosozumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Romosozumab. |
| Ropeginterferon alfa-2b | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Ropivacaine. |
| Rotavirus vaccine | The therapeutic efficacy of the Rotavirus vaccine can be decreased when used in combination with Ofatumumab. |
| Rubella virus vaccine | The risk or severity of infection can be increased when the Rubella virus vaccine is combined with Ofatumumab. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ruxolitinib. |
| Sacituzumab govitecan | The risk or severity of adverse effects can be increased when Ofatumumab is combined with sacituzumab govitecan. |
| Sarilumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sarilumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Satralizumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Secukinumab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ofatumumab. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Ofatumumab. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of the Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ofatumumab. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Ofatumumab. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Spesolimab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Ofatumumab. |
| Sulesomab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sulesomab. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ofatumumab. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ofatumumab. |
| Sunitinib | The risk or severity of adverse effects can be increased when Sunitinib is combined with Ofatumumab. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sutimlimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated estrogen, A may increase the thrombogenic activities of Ofatumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated estrogen, B may increase the thrombogenic activities of Ofatumumab. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Ofatumumab. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tafasitamab. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Ofatumumab. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Temsirolimus is combined with Ofatumumab. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Ofatumumab. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ofatumumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Teriflunomide. |
| Tetanus immune globulin, human | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tetanus immune globulin, human. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Tetracaine. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tezepelumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Ofatumumab. |
| Thiotepa | The risk or severity of adverse effects can be increased when Thiotepa is combined with Ofatumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Ofatumumab. |
| Tick-borne encephalitis vaccine (whole virus, inactivated) | The therapeutic efficacy of the Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ofatumumab. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tildrakizumab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Ofatumumab. |
| Tisotumab vedotin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tisotumab vedotin. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tixagevimab. |
| Tixocortol | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tixocortol. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Tocilizumab is combined with Ofatumumab. |
| Tofacitinib | Ofatumumab may increase the immunosuppressive activities of Tofacitinib. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Ofatumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Ofatumumab. |
| Trabectedin | The risk or severity of adverse effects can be increased when Trabectedin is combined with Ofatumumab. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tralokinumab. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Ofatumumab. |
| Trastuzumab deruxtecan | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Trastuzumab deruxtecan. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ofatumumab. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Ofatumumab. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ofatumumab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ofatumumab. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Ofatumumab. |
| Typhoid vaccine | The therapeutic efficacy of the Typhoid vaccine can be decreased when used in combination with Ofatumumab. |
| Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ofatumumab. |
| Typhoid Vi polysaccharide vaccine | The therapeutic efficacy of the Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ofatumumab. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Upadacitinib. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ofatumumab. |
| Varicella zoster vaccine (live/attenuated) | The risk or severity of infection can be increased when the Varicella zoster vaccine (live/attenuated) is combined with Ofatumumab. |
| Varicella zoster vaccine (recombinant) | The therapeutic efficacy of the Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ofatumumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Vedolizumab. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholera CVD 103-HgR strain live antigen can be decreased when used in combination with Ofatumumab. |
| Vilanterol | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Vilanterol. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Ofatumumab. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Ofatumumab. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Ofatumumab. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ofatumumab. |
| Voclosporin | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Voclosporin. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Ofatumumab. |
| Yellow fever vaccine | The risk or severity of infection can be increased when the Yellow fever vaccine is combined with Ofatumumab. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Ofatumumab. |
Pregnancy and Lactation
FDA Pregnancy Category C
Pregnancy
This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately.
Women who may become pregnant should use effective birth control when receiving ofatumumab and for at least 6 months after treatment has ended.
Breast-feeding
It is not known if ofatumumab passes into breast milk. If you are breastfeeding and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breastfeeding.
Children: The safety and effectiveness of using this medication have not been established for children.
Seniors: The safety and effectiveness of using this medication have not been established for adults older than 55 years of age.
Hepatitis B reactivation: People who have a hepatitis B infection that is dormant may experience the infection returning, causing further liver dysfunction or liver failure. If you have a history of hepatitis B infection, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.
If you experience symptoms of worsening liver function, such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.
Infections: Ofatumumab can affect the way your body’s natural defenses work to fight infection. This makes the body more likely to develop infections due to bacteria, viruses, and fungi. This effect is increased if you are taking ofatumumab with other medications that reduce the body’s ability to fight infection. If you have a history of chronic or frequent infections, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.
Contact your doctor right away if you notice symptoms of a serious infection, such as fever, chills, headache, flu-like symptoms, feeling tired, cough, blood in the sputum, shortness of breath, night sweats, weight loss, nausea, vomiting, diarrhea, frequency or burning while passing urine, redness or swelling of skin or joints, cold sores, tooth pain, or new or worsening pain in any part of the body.
Progressive multifocal leukoencephalopathy (PML): There have been reports of PML after using ocrelizumab. PML is a rare disorder that causes nerve damage in the brain. If you experience memory loss, vision loss, trouble thinking, or difficulty walking, contact your doctor immediately.
Vaccinations: This medication may interfere with the effectiveness of certain vaccines. Before starting treatment with this medication, check with your doctor to ensure your immunizations are up to date. Any required vaccinations with live vaccines should be completed at least 4 weeks before starting and vaccinations with inactivated vaccines completed at least 2 weeks before starting treatment with ofatumumab.
What special precautions should I follow?
Before receiving an ofatumumab injection,
- tell your doctor and pharmacist if you are allergic to ofatumumab, any other medications, or any of the ingredients in the ofatumumab injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had the chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways)
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving an ofatumumab injection, call your doctor.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving an ofatumumab injection.
- ask your doctor whether you should receive any vaccinations before you begin your treatment with ofatumumab. Do not have any vaccinations during your treatment without talking to your doctor.
References
